N/A
Completed N=10
Bariatric Embolization of Arteries With Imaging Visible Embolics (BEATLES)
Source: ClinicalTrials.gov NCT04197336 ↗Enrolled (actual)
10
Serious AEs
30.0%
Results posted
Mar 2025
Primary outcomePrimary: Change in Body Weight as Assessed by BMI (kg/m^2) — 43.7 kg/m^2
Summary
The BEATLES study is an investigator-initiated, prospective, double-blinded, randomized, sham-controlled study that will assess the impact of bariatric embolization on the systemic levels of obesity-related hormones and, as a consequence, on weight loss. The goal of this study is to help treat obesity combining a lifestyle program and a minimally invasive, angiographic (i.e., through blood vessels) approach.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Change in Body Weight as Assessed by BMI (kg/m^2) |
43.7 | — |
| PRIMARY Change in Body Weight (Pounds) |
14.3 | — |
Eligibility Criteria
Inclusion Criteria
- Male or female, aged ≥21 and ≤70 years
- Willing, able, and mentally competent to provide written informed consent
- Obese patients with a BMI ≥35 kg/m2
- Weight ≤400 lb
- Vascular anatomy (including celiac, hepatic, and gastric arteries) that in the opinion of the interventional radiologist is amendable to bariatric embolization, as assessed via 3D CT angiography
- Suitable for protocol therapy, as determined by the interventional radiology investigator
- Adequate hematologic (neutrophils>1.5x109/L, platelets>70x109/L, international normalized ratio (INR 60milliliter mL/min. 1.73m2) function
- For females of reproductive potential: agreement to use of highly effective contraception
- for duration of study participation
- Patients who have failed conservative weight loss therapies such as supervised low calorie diets combined with behavior therapy and exercise
- Live or work within 65 miles of the enrolling institution in case a catastrophic post embolization event occurs
Exclusion Criteria
- hemoglobin A1c greater than 8%
- Patients who are currently taking either Insulin or sulfonylurea (medication changes are allowed)
- Prior history of gastric, pancreatic, hepatic, and/or splenic surgery
- Prior radiation therapy to the upper abdomen
- Prior embolization to the stomach, spleen, or liver
- Cirrhosis
- Known portal venous hypertension
- Active peptic ulcer disease
- Significant risk factors for peptic ulcer disease, including daily NSAID use
- Large hiatal hernia, defined as >5 cm in size
- Active H. Pylori infection
- Known aortic pathology, such as aneurysm or dissection
- Renal insufficiency, as evidenced by an estimated glomerular filtration rate of <60 milliliter(mL)/min
- Major comorbidity, such as active cancer, significant cardiovascular disease, or peripheral arterial disease
- Pregnancy
- Pre-existing chronic abdominal pain
- Positive stool occult blood study
- GI bleeding or bleeding diathesis within 5 years
- Weight loss (intentional or unintentional) of more than or equal to 5% of body weight in the 6 months prior to randomization
- A weight loss greater than 6lb during the weight management run- in
- Use of anti-obesity medications in the 12 months prior to screening
- Endoscopic findings that would preclude bariatric embolization (at the discretion of the study team)
- History of gastric motility disorders or an abnormal nuclear gastric motility examination (to be performed in diabetic subjects only)
- American Society of Anesthesiologists Class 4 or 5 (very high risk surgical candidates: class 4=incapacitating disease that is a constant threat to life) at the time of screening for enrollment into the study - this exclusion criterion exists, because of the possibility that surgical intervention will be needed if the study intervention subsequently leads to severe adverse effects
- Inflammatory bowel disease
- Autoimmune disease or HIV+
- History of allergy to iodinated contrast media
- Failure to comply with pre-procedure weight management "run-in", or other pre-procedural visits (specifically, participants must complete 80% of weight management and Lose It! Food tracking, and 100% of one-time visits, i.e. MRI, computed tomography angiography (CTA), endoscopy)
- Applicability of any contraindication regarding patient's vasculature as per Instruction for Use
- Inability to have an MRI scan (i.e., metal implants or claustrophobia)
- Smokers/vape users/tobacco use
- Active or new-onset endocrine disorders (stable disease acceptable)
- Other unforeseen conditions that may make patients unsuitable for the procedure (study team discretion)
Exclusion Criteria (Psychiatric):
- As determined by clinical judgment based on Clinical Interview, psychological/behavioral measures, medical records, previous mental health records/other collateral information (as available) and consistent with diagnostic and statistical manual of mental disorders (DSM) -5 criteria:
- Diagnosis of severe mental illnes
Data sourced from ClinicalTrials.gov (NCT04197336). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.